Bezos, Paul Allen funds, a16z put up $100M to build an Illumina of human proteins
Beaming in from the wooden table of his West Coast home, an 80-year-old Lee Hartwell recalls the early days of the genomic revolution, when it seemed like cancer might become the answer to an equation: Learn its genetic basis, learn its antidote.
The 2001 Nobel Prize winner was still president of the Fred Hutchinson Cancer Research Center during those early years, at the start of the millennium. The idea held promise then, he said. Reality has been tougher.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 99,000+ biopharma pros reading Endpoints daily — and it's free.